In a similar 12 months the ITC also documented on their endeavours to the move syntheses of two direct compounds described before by AstraZeneca. The 1st one particulars the movement synthesis of the strong 5HT1B antagonist (28) which was assembled by way of a 5 stage steady synthesis which include a SNAr response, heterogeneous hydrogenation, Mich